MYOV · Myovant Sciences Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '22 | Q1 '23 | Q1 '22 | Q3 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.23M | $104.82M | $116.49M | $33.33M | $54.44M | $0 | $1.38M | $0 | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $31.52M | $26.92M | $23.89M | $30.88M | $25.73M | $44.19M | $30.45M | $40.52M | $51.12M | $48.93M |
| SG&A | $86.38M | $84.26M | $79.03M | $61.21M | $72.13M | $22.83M | $49.24M | $31.32M | $14.15M | $29.14M |
| Total Operating Expenses | - | - | - | - | - | $67.01M | $79.70M | $71.84M | $65.27M | $78.07M |
| D&A | - | - | $321.0K | - | - | - | - | - | - | - |
| Operating Income | ($51.90M) | ($33.71M) | ($9.36M) | ($57.32M) | ($59.74M) | ($33.68M) | ($78.32M) | ($71.84M) | ($67.59M) | ($85.41M) |
| Interest Expense | $6.12M | $4.81M | $4.20M | $3.50M | $3.48M | - | $2.61M | - | $3.79M | $3.64M |
| Income Tax | $1.21M | $8.11M | $8.16M | $911.0K | $296.0K | $672.0K | ($1.15M) | ($134.0K) | $313.0K | $191.0K |
| Net Income | ($57.63M) | ($45.62M) | ($21.24M) | ($61.66M) | ($63.45M) | ($32.86M) | ($73.85M) | ($67.06M) | ($67.90M) | ($85.60M) |
| EPS - Basic | ($0.59) | ($0.47) | ($0.22) | ($0.67) | ($0.82) | - | - | - | - | - |
| EPS - Diluted | ($0.59) | ($0.47) | ($0.22) | ($0.37) | ($0.68) | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '22 | Q1 '23 | Q1 '22 | Q3 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $250.59M | $341.96M | $325.54M | $406.70M | $457.74M | $674.49M | $713.52M | $94.21M | $76.64M | $83.07M |
| Accounts Receivable | $41.02M | $33.76M | $29.65M | $23.30M | $18.91M | $3.57M | - | - | $0 | - |
| Inventory | $30.08M | $23.05M | $21.22M | $7.58M | $6.74M | $2.61M | - | - | $0 | - |
| Accounts Payable | $12.22M | $8.21M | $9.55M | $12.25M | $12.13M | $17.81M | $12.36M | $7.01M | $15.33M | $6.62M |
| Current Assets | $386.59M | $460.91M | $426.83M | $488.14M | $574.75M | $704.64M | $754.03M | $116.91M | $87.91M | $110.97M |
| Total Assets | $403.52M | $483.97M | $460.13M | $520.01M | $604.29M | $725.03M | $774.21M | $135.77M | $105.93M | $129.51M |
| Current Liabilities | $245.75M | $251.69M | $226.24M | $250.33M | $269.04M | $281.34M | $252.07M | $66.76M | $85.92M | $53.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | $0 | $0 |
| Total Liabilities | $961.66M | $997.22M | $943.65M | $993.49M | $1.04B | $1.08B | $1.04B | $335.55M | $214.20M | $178.40M |
| Stockholders' Equity | ($558.14M) | ($513.25M) | ($483.52M) | ($473.48M) | ($432.28M) | ($353.96M) | ($270.66M) | ($199.78M) | ($108.28M) | ($48.89M) |
| Retained Earnings | ($1.38B) | ($1.32B) | ($1.27B) | ($1.25B) | ($1.19B) | ($1.05B) | ($964.78M) | ($890.94M) | ($791.01M) | ($726.10M) |
Cash Flow
| Line item | Q3 '23 | Q2 '22 | Q1 '23 | Q1 '22 | Q3 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($76.00M) | ($113.18M) | - | ($61.98M) | - | - | ($66.81M) | - |
| Investing Cash Flow | - | - | ($5.74M) | ($74.39M) | - | ($12.12M) | - | - | ($139.0K) | - |
| Financing Cash Flow | - | - | $1.19M | $4.13M | - | $82.19M | - | - | $137.61M | - |
| CapEx | - | - | $72.0K | $0 | - | $151.0K | - | - | $139.0K | - |
| Free Cash Flow | - | - | ($76.08M) | ($113.18M) | - | ($62.13M) | - | - | ($66.95M) | - |
Ratios
| Metric | Q3 '23 | Q2 '22 | Q1 '23 | Q1 '22 | Q3 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -51.8% | -32.2% | -8.0% | -172.0% | -109.7% | - | -5679.3% | - | - | - |
| EBITDA margin | - | - | -7.8% | - | - | - | - | - | - | - |
| Net margin | -57.5% | -43.5% | -18.2% | -185.0% | -116.5% | - | -5355.3% | - | - | - |
| Free cash flow margin | - | - | -65.3% | -339.5% | - | - | - | - | - | - |
| FCF / Net income | - | - | 3.58 | 1.84 | - | 1.89 | - | - | 0.99 | - |
| R&D / Revenue | 31.4% | 25.7% | 20.5% | 92.6% | 47.3% | - | 2208.3% | - | - | - |
| SG&A / Revenue | 86.2% | 80.4% | 67.8% | 183.6% | 132.5% | - | 3570.9% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.3% | -9.4% | -4.6% | -11.9% | -10.5% | -4.5% | -9.5% | -49.4% | -64.1% | -66.1% |
| Return on equity | 10.3% | 8.9% | 4.4% | 13.0% | 14.7% | 9.3% | 27.3% | 33.6% | 62.7% | 175.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.57 | 1.83 | 1.89 | 1.95 | 2.14 | 2.50 | 2.99 | 1.75 | 1.02 | 2.08 |
| Quick ratio | 1.45 | 1.74 | 1.79 | 1.92 | 2.11 | 2.50 | 2.99 | 1.75 | 1.02 | 2.08 |
| Cash ratio | 1.02 | 1.36 | 1.44 | 1.62 | 1.70 | 2.40 | 2.83 | 1.41 | 0.89 | 1.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -8.5x | -7.0x | -2.2x | -16.4x | -17.2x | - | -30.0x | - | -17.8x | -23.5x |
| Equity multiplier | -0.72 | -0.94 | -0.95 | -1.10 | -1.40 | -2.05 | -2.86 | -0.68 | -0.98 | -2.65 |
| Liabilities / Assets | 2.38 | 2.06 | 2.05 | 1.91 | 1.72 | 1.49 | 1.35 | 2.47 | 2.02 | 1.38 |
| Efficiency | ||||||||||
| Asset turnover | 0.25 | 0.22 | 0.25 | 0.06 | 0.09 | 0.00 | 0.00 | 0.00 | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 149d | 118d | 93d | 255d | 127d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 84.1% | - | 249.5% | - | 3847.8% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.1% | 53.1% | 83.7% | -70.2% | 23.7% | 50.2% | 8.3% | -2.1% | -9.0% | -20.9% |
| Net income growth (YoY) | 9.2% | 32.0% | 65.6% | -87.6% | 14.1% | 51.6% | 13.7% | 5.0% | -9.3% | -21.2% |
| EPS growth (YoY) | 13.2% | - | 40.5% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 32.8% | -82.1% | - | 7.2% | - | - | -48.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -29.1% | -156.9% | -2.1% | -33.8% | -59.7% | -226.9% | -453.6% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-03-31.
Product / service
$237.28M totalProduct$94.31M · 39.7%
ORGOVYX$82.96M · 35.0%
License And Service$31.67M · 13.3%
Revenue Recognized Upon Completion Of Delivery$16.70M · 7.0%
MYFEMBREE$6.36M · 2.7%
Richter Product Supply And Royalties$5.00M · 2.1%
RYEQO$300.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Myovant Sciences Ltd. against the 5 most active filers in the same SIC group.